Summit Therapeutics Inc. SMMT · Stock Open Summit Therapeutics Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Summit Therapeutics Inc. Analysis (SMMT)
Is Summit Therapeutics Inc. a good investment? Summit Therapeutics Inc. (SMMT) is currently trading at 16.17 USD. Market analysts have a consensus price target of 30.29 USD. This suggests a potential upside from current levels.
Earnings Schedule: Summit Therapeutics Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -1.17.
Investor FAQ
Does Summit Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Summit Therapeutics Inc.?
Summit Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -1.11.
Company Profile
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Community Discussion